COMPARISON OF INTRA-ARTICULAR SHAM AND VEHICLE INJECTION FROM A PHASE 2B TRIAL OF SM04690, A SMALL-MOLECULE WNT INHIBITOR, FOR KNEE OSTEOARTHRITIS

被引：1

作者：

Yazici, Y. ^{[1
]}

Tambiah, J. ^{[1
]}

Swearingen, C. ^{[1
]}

Kennedy, S. ^{[1
]}

Strand, V. ^{[2
]}

Cole, B. ^{[3
]}

Hochberg, M. ^{[4
]}

Bannuru, R. ^{[5
]}

McAlindon, T. ^{[5
]}

机构：

[1] Samumed, San Diego, CA USA

[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[3] Rush Univ, Midwest Orthopaed, Chicago, IL 60612 USA

[4] Univ Maryland, Baltimore, MD 21201 USA

[5] Tufts Univ, Med Ctr, Boston, MA 02111 USA

来源：

OSTEOARTHRITIS AND CARTILAGE | 2019年 / 27卷

关键词：

D O I：

10.1016/j.joca.2019.02.605

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

340

引用

页码：S241 / S242

页数：2

共 50 条

[31] Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis
Yazici, Yusuf
McAlindon, Timothy E.
Gibofsky, Allan
Lane, Nancy E.
Clauw, Daniel J.
Armas, Eddie
Skrepnik, Nebojsa
Swearingen, Christopher J.
DiFrancesco, Anita
Tambiah, Jeymi
Hochberg, Marc
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[32] RESULTS FROM A 52-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR WNT PATHWAY INHIBITOR (SM04690) FOR THE TREATMENT OF KNEE OSTEOARTHRITIS
Yazici, Y.
McAlindon, T. E.
Gibofsky, A.
Lane, N. E.
Clauw, D. J.
Jones, M. H.
Bergfeld, J.
Swearingen, C. J.
DiFrancesco, A.
Tambiah, J. R.
Hochberg, M.
OSTEOARTHRITIS AND CARTILAGE, 2018, 26 : S293 - S294
[33] INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
Simsek, I.
Swearingen, C.
Kennedy, S.
Tambiah, J.
Damatarca, C.
Yazici, Y.
Lane, N.
Hochberg, M.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 117 - 117
[34] INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
Kennedy, Sarah
Simsek, Ismail
Swearingen, Christopher J.
Tambiah, Jeyanesh
Damatarca, Cristina
Yazici, Yusuf
Lane, Nancy E.
Hochberg, Marc C.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 121 - 121
[35] Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, Provided Cartilage-Protective Effects in an Animal Model of Post-traumatic OA
Seo, Timothy
Deshmukh, Vishal
Yazici, Yusuf
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1961 - 1963
[36] Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
Simsek, Ismail
Swearingen, Chris
Kennedy, Sarah
Tambiah, Jeyanesh
Yazici, Yusuf
Lane, Nancy
Hochberg, Marc C.
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[37] INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (LOR; SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
Simsek, I.
Swearingen, C.
Kennedy, S.
Tambiah, J.
Damatarca, C.
Yazici, Y.
Lane, N.
Hochberg, M.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S606 - S607
[38] RADIOGRAPHIC OUTCOMES FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, INJECTABLE, WNT PATHWAY INHIBITOR (SM04690) IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE: WEEK 26 INTERIM ANALYSIS
Yazici, Y.
McAlindon, T. E.
Gibofsky, A.
Lane, N. E.
Skrepnik, N.
Armas, E.
Swearingen, C. J.
DiFrancesco, A.
Tambiah, J. R.
Hochberg, M. C.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 121 - 121
[39] LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK2/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, PROVIDED CARTILAGE-PROTECTIVE EFFECTS IN AN ANIMAL MODEL OF POST-TRAUMATIC OA
Seo, T.
Deshmukh, V.
Yazici, Y.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 60 - 60
[40] CLINICAL OUTCOMES FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, INJECTABLE, WNT PATHWAY INHIBITOR (SM04690) FOR THE TREATMENT OF KNEE OSTEOARTHRITIS: WEEK 26 INTERIM ANALYSIS
Yazici, Y.
Gibofsky, A.
Lane, N. E.
Skrepnik, N.
Armas, E.
Swearingen, C. J.
DiFrancesco, A.
Tambiah, J. R.
McAlindon, T. E.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 985 - 986

← 1 2 3 4 5 →